Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 567-573

  Gaseitsiwe, Simani ^a,b   Valentini, Davide ^a   Ahmed, Raija ^a,b   Mahdavifar, Shahnaz ^a,b   Magalhaes, Isabelle ^a,b   Zerweck, Johannes ^c   Schutkowski, Mike ^c   Gautherot, Emmanuel ^d   Montero, Felix ^d   Ehrnst, Anneka ^a   Reilly, Marie ^a   Maeurer, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c JPT Peptide Technologies GmbH   (Germany)

^d BECKMAN COULTER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS 1 PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN; PEPTIDE LIBRARY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING ASSAY; CD4+ T LYMPHOCYTE; CLUSTER ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DNA MICROARRAY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1B; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; VACCINE PRODUCTION;

EPITOPE MAPPING; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV; HIV ENVELOPE PROTEIN GP160; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING;

EID: 64549095249     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00441-08     Document Type: Article

References (46)

1. Angyalosi, G., R. Neveu, I. Wolowczuk, A. Delanoye, J. Herno, C. Auriault, and V. Pancre. 2001. HLA class II polymorphism influences onset and severity of pathology in Schistosoma mansoni-infected transgenic mice. Infect. Immun. 69:5874-5882.
2. Axon Instruments Inc. 2005. Acuity 4.0 microarray informatics software user's guide, 2005. Axon Instruments/Molecular Devices Corp., Sunnyvale, CA.
3. Castellino, F., G. Zhong, and R. N. Germain. 1997. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum. Immunol. 54:159-169.
4. Deeks, S. G., and B. D. Walker. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416.
5. DeLuca, D. S., B. Khattab, and R. Blasczyk. 2007. A modular concept of HLA for comprehensive peptide binding prediction. Immunogenetics 59:25-35.
6. Dengjel, J., M. D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Muller, B. Kramer, A. Missiou, M. Sauter, J. Hennenlotter, D. Wernet, A. Stenzl, H. G. Rammensee, K. Klingel, and S. Stevanovic. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 12:4163-4170.
7. Dengjel, J., H. G. Rammensee, and S. Stevanovic. 2005. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 40:100-104.
8. Erlich, H. A., and U. B. Gyllensten. 1991. The evolution of allelic diversity at the primate major histocompatibility complex class II loci. Hum. Immunol. 30:110-118.
9. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B. Haynes, N. L. Letvin, B. D. Walker, B. H. Hahn, and B. T. Korber. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106.
10. Fonseca, S. G., A. Coutinho-Silva, L. A. Fonseca, A. C. Segurado, S. L. Moraes, H. Rodrigues, J. Hammer, E. G. Kallas, J. Sidney, A. Sette, J. Kalil, and E. Cunha-Neto. 2006. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS 20:2263-2273.
11. Frank, R. 2002. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports-principles and applications. J. Immunol. Methods 267:13-26.
12. Gaudebout, P., D. Zeliszewski, J. J. Golvano, C. Pignal, S. Le Gac, F. Borras-Cuesta, and G. Sterkers. 1997. Binding analysis of 95 HIV gp120 peptides to HLA-DR1101 and -DR0401 evidenced many HLA-class II binding regions on gp120 and suggested several promiscuous regions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14:91-101.
13. Godkin, A. J., K. J. Smith, A. Willis, M. V. Tejada-Simon, J. Zhang, T. Elliott, and A. V. Hill. 2001. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J. Immunol. 166:6720-6727.
14. Gowthaman, U., and J. N. Agrewala. 2008. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J. Proteome Res. 7:154-163.
15. Kaufmann, D. E., P. M. Bailey, J. Sidney, B. Wagner, P. J. Norris, M. N. Johnston, L. A. Cosimi, M. M. Addo, M. Lichterfeld, M. Altfeld, N. Frahm, C. Brander, A. Sette, B. D. Walker, and E. S. Rosenberg. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78:4463-4477.
16. Kobayashi, H., M. Wood, Y. Song, E. Appella, and E. Celis. 2000. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60:5228-5236.
17. Letourneau, S., E. J. Im, T. Mashishi, C. Brereton, A. Bridgeman, H. Yang, L. Dorrell, T. Dong, B. Korber, A. J. McMichael, and T. Hanke. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984.
18. Magalhaes, I., N. K. Vudattu, E. Jäger, and M. J. Maeurer. 2008. Tumor antigen-specific T-cells are present in the CD8alpha/alpha+ T-cell effector-memory pool. J. Immunother. 31:840-848.
19. Malhotra, U., S. Holte, T. Zhu, E. Delpit, C. Huntsberry, A. Sette, R. Shankarappa, J. Maenza, L. Corey, and M. J. McElrath. 2003. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J. Virol. 77:2663-2674.
20. Mallios, R. R. 2003. A consensus strategy for combining HLA-DR binding algorithms. Hum. Immunol. 64:852-856.
21. Martin, M. P., and M. Carrington. 2005. Immunogenetics of viral infections. Curr. Opin. Immunol. 17:510-516.
22. Middleton, D., L. Menchaca, H. Rood, and R. Komerofsky. 2003. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61: 403-407.
23. Nahtman, T., A. Jernberg, S. Mahdavifar, J. Zerweck, M. Schutkowski, M. Maeurer, and M. Reilly. 2007. Validation of peptide epitope microarray experiments and extraction of quality data. J. Immunol. Methods 328:1-13.
24. Ndung'u, T., S. Gaseitsiwe, E. Sepako, F. Doualla-Bell, T. Peter, S. Kim, I. Thior, V. A. Novitsky, and M. Essex. 2005. Major histocompatibilitycomplex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. Clin. Diagn. Lab. Immunol. 12:1020-1028.
25. Newman, M. J., B. Livingston, D. M. McKinney, R. W. Chesnut, and A. Sette. 2002. T-lymphocyte epitope identification and their use in vaccine development for HIV-1. Front. Biosci. 7:d1503-d1515.
26. Nielsen, M., C. Lundegaard, T. Blicher, B. Peters, A. Sette, S. Justesen, S. Buus, and O. Lund. 2008. Quantitative predictions of peptide binding to any HLA-DR molecule ofknownsequence: NetMHCIIpan. PLoS Comput. Biol. 4:e1000107.
27. Nielsen, M., C. Lundegaard, and O. Lund. 2007. Predictionof MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinform. 8:238.
28. Novak, E. J., A. W. Liu, G. T. Nepom, and W. W. Kwok. 1999. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Investig. 104:R63-R67.
29. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
30. Scharn, D., H. Wenschuh, U. Reineke, J. Schneider-Mergener, and L. Germeroth. 2000. Spatially addressed synthesis of amino-and amino-oxy-substituted 1,3,5-triazine arrays on polymeric membranes. J. Comb. Chem. 2:361-369.
31. Schena, M. 2005. Protein microarray, vol. 1. Jones and Bartlett, Sudbury, MA. 32. Sercarz, E. E., and E. Maverakis. 2003. Mhc-guided processing: binding of large antigen fragments. Nat. Rev. Immunol. 3:621-629.
32. Sette, A., L. Adorini, S. M. Colon, S. Buus, and H. M. Grey. 1989. Capacityof intact proteins to bind to MHC class II molecules. J. Immunol. 143:1265-1267.
33. Sidney, J., S. Southwood, C. Oseroff, M. F. del Guercio, A. Sette, and H. M. Grey. 2001. Measurement of MHC/peptide interactions by gel filtration, chapter 18, unit 18.3. Current protocols in immunology. John Wiley & Sons, Hoboken, NJ.
34. Siebold, C., B. E. Hansen, J. R. Wyer, K. Harlos, R. E. Esnouf, A. Svejgaard, J. I. Bell, J. L. Strominger, E. Y. Jones, and L. Fugger. 2004. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc. Natl. Acad. Sci. USA 101:1999-2004.
35. Sinigaglia, F., M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778-780.
36. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363-3373.
37. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-221.
38. Stone, J. D., W. E. Demkowicz, Jr., and L. J. Stern. 2005. HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. Proc. Natl. Acad. Sci. USA 102:3744-3749.
39. Tong, J. C., T. W. Tan, and S. Ranganathan. 2007. Methods and protocols for prediction of immunogenic epitopes. Brief. Bioinform. 8:96-108.
40. Topalian, S. L. 1994. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:741-745.
41. Wahlstrom, J., J. Dengjel, B. Persson, H. Duyar, H. G. Rammensee, S. Stevanovideltac, A. Eklund, R. Weissert, and J. Grunewald. 2007. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Investig. 117:3576-3582.
42. Walter, W., C. Scheuer, M. Loos, T. E. Reichert, and M. J. Maeurer. 2001. H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice. J. Biol. Chem. 276: 11086-11091.
43. Wang, P., J. Sidney, C. Dow, B. Mothe, A. Sette, and B. Peters. 4 April 2008, posting date. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4:e1000048.
44. Williams, F., A. Meenagh, R. Single, M. McNally, P. Kelly, M. P. Nelson, D. Meyer, A. Lancaster, G. Thomson, and D. Middleton. 2004. High resolution HLA-DRB1 identification of a Caucasian population. Hum. Immunol. 65: 66-77.
45. Zhan, X., K. S. Slobod, S. Surman, S. A. Brown, T. D. Lockey, C. Coleclough, P. C. Doherty, and J. L. Hurwitz. 2003. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J. Virol. 77:4231-4236.
46. Zhu, S., K. Udaka, J. Sidney, A. Sette, K. F. Aoki-Kinoshita, and H. Mamitsuka. 2006. Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules. Bioinformatics 22:1648-1655.